Mankind Pharma (MANKIND.NS)

Executive Summary

Mankind Pharma Limited is India's leading pharmaceutical company specializing in branded generic drugs, consumer healthcare, and active pharmaceutical ingredients. Founded in 1995 and headquartered in New Delhi, the company has built a robust distribution network reaching Tier II-IV cities and rural markets, ensuring wide accessibility of affordable healthcare. With a market capitalization of approximately ₹936 billion, Mankind Pharma operates seven R&D centers and has a strong commercial portfolio, including one approved product and 19 publications. The company's business model focuses on high-volume, low-cost generics, which has driven consistent revenue growth and market share expansion in domestic and international markets. Recent clinical developments highlight Mankind Pharma's efforts to expand its pipeline. The company has completed a Phase 3 trial for a generic bimatoprost ophthalmic solution (0.01%) for open-angle glaucoma, positioning it for potential approval and launch. Additionally, its Phase 2 trial for MKP10241, targeting type 2 diabetes mellitus and obesity, is actively recruiting with a completion date in April 2026. These programs, combined with the company's strong operational execution and market presence, support a positive outlook. Key upcoming catalysts include Phase 2 readouts and potential regulatory approvals, which could drive further value.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 readout for MKP10241 (T2DM/Obesity)65% success
• Q3 2026Potential approval/launch of generic Bimatoprost 0.01% Ophthalmic Solution85% success